|1||Enhanced by machine learning, together with artificial intelligence, to help in all medical situations|
|2||An industry first medical diagnostics application with USA, EU, China provisional Patents secured.|
|3||Key automotive safety suppliers and hospitals are first to provide intent and usability of patent.|
|4||$57B market size in telemedicine, medical diagnostics and monitoring has a 5 year 14% CAGR|
|5||Transportation connectivity solutions market size is projected to reach $227B by 2025 with 27% CAGR|
|6||Founders had 4 startups with multiple exits, patents and has 20+ years in AI, AR and software|
|7||Assessments of Covid vitals through visualized AI and machine learning can address pandemic care|
|8||Team and Board has strong expertise in machine learning, AI, augmented reality, medicine, software|
I want to invest in Marux because I used to work in the medical field and understand that every second counts when responding to a medical emergency situation. With Marux’s technology I believe it will help improve the response times related to medical emergencies.
This technology will save lives and provide 1st responders/medical professionals a diagnostic tool to “go where no man has gone before”.
Imagine watching the movie Star Trek and you see one of the officers use a device to receive vital signs of an injured person or a person who has fallen down. The information from the device can help save precious time in a emergency and it can also help doctors receive a patient from a firefighter or paramedic. This is what MARUX® is capable of doing but it can be used from a mobile phone, tablet or any smartphone device captured from its basic video camera lens.
Time is essential and vital in all medical responsiveness needs. MARUX® can help save time in properly assessing and doing a pre-diagnostic on incoming patients. We currently have multiple Provisional Patent Applications - 62941150, 63033698, 63085422 that are in place for U.S.A., EU, and China.
We believe that MARUX® can become the default interface application for all emergency medical responders (EMR), emergency medical systems (EMS) and within all of the healthcare ecosystems. Our secured multi-patents in provision, simplifies video analytics for transformation of vital medical diagnostics into reliable medical assets for quicker and more pinpoint medical care.
MARUX® will focus its application development on emergency call systems, remote monitoring/diagnostics, and medical database channels. These inputs, along with an injured person’s emergency data, vitals, and geographical data, will be forwarded to medical responders. Every split second could be vital for addressing both emergency and non-emergency calls. MARUX® can help make medical responsiveness more efficient and predictive.
We have two U.S. provisional patents secured for our data process flow, integrated AI and real-time data capture software. MARUX® has the ability to capture facial analysis and physical biometrics of the patient/occupant from standard 4K video cameras. These strategically placed devices can be in any mode of transportation in the event of an unexpected emergency and placed in residences or senior assisted homes, where the most common calls occur for EMS responders.
We have artificial intelligence (AI) data for key assessments of the most common occupant injuries (head, neck, upper/lower torso). Our team has also developed the integrated processes of machine learning and AI for many of the medical databases. Our on going work of customizing an easily adaptable dashboard for the collection and output of patient vitals and physical assessments is key for our market channels.
We currently have commitment letters from international automotive suppliers for the use of our pilot program. As well as, a scaled role out of our capabilities within a few key major metropolitan hospitals and EMS groups.
The MARUX® core team and Board of Directors is comprised of a unique balance of digital health, technology, software development, EMR and medical experiences. The Founders team brings previous successful startup experience, multiple go-to-market product/software launches in the automotive industry. MARUX® Board of Directors brings a combined 35 years of EMS and hospital experience as well as published digital health industry leaders with an educational background from Harvard and MIT. Every member of the team has a passion for helping others, improving the health/medical field, and shares the vision of the high potential benefits that MARUX® will provide.
MARUX® has financial statements ending December 31 2019. Our cash in hand is $1,200, as of August 2020. Over the three months prior, revenues averaged $0/month, cost of goods sold has averaged $0/month, and operational expenses have averaged $400/month.
Management’s Discussion and Analysis of Financial Condition and Results of Operations
You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes and other financial information included elsewhere in this offering. Some of the information contained in this discussion and analysis, including information regarding the strategy and plans for our business, includes forward-looking statements that involve risks and uncertainties. You should review the "Risk Factors" section for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.
Imagine watching the movie Star Trek and you see one of the officers use a device to receive vital signs of an injured person or a person who has fallen down. The information from the device can help save precious time in a emergency, and will help doctors receive in a patient from a firefighter or paramedic. This is what MARUX is capable of doing but it can be used from a mobile phone, tablet or any smartphone device; with visual data captured from a basic video camera.
We would like to see MARUX, as the default interface application, for all emergency medical responders (EMR) emergency medical systems (EMS) and all emergency hospital rooms. We would also like to see MARUX available in every new and existing mode of transportation, available in every home, senior living centers and other facilities where monitoring the health/well-being of people are vitally important.
Given the Company’s limited operating history, the Company cannot reliably estimate how much revenue it will receive in the future, if any.
MARUX, Inc. was incorporated in the State of Michigan in December 2019. The aforementioned patents are owned by two of the company's founders, Michael D'Orazio and Jonathan Rayos.
Since then, we have:
Historical Results of Operations
Our company was organized in December 2019 and has limited operations upon which prospective investors may base an evaluation of its performance.
Liquidity & Capital Resources
After the conclusion of this Offering, should we hit our minimum funding target, our projected runway is 12 months before we need to raise further capital.
We plan to use the proceeds as set forth in this Form C under "Use of Funds". We don’t have any other sources of capital in the immediate future.
We will likely require additional financing in excess of the proceeds from the Offering in order to perform operations over the lifetime of the Company. We plan to raise capital in 6 months. Except as otherwise described in this Form C, we do not have additional sources of capital other than the proceeds from the offering. Because of the complexities and uncertainties in establishing a new business strategy, it is not possible to adequately project whether the proceeds of this offering will be sufficient to enable us to implement our strategy. This complexity and uncertainty will be increased if less than the maximum amount of securities offered in this offering is sold. The Company intends to raise additional capital in the future from investors. Although capital may be available for early-stage companies, there is no guarantee that the Company will receive any investments from investors.
Runway & Short/Mid Term Expenses
MARUX, Inc. cash in hand is $1,200, as of July 2020. Over the last three months, revenues have averaged $0/month, cost of goods sold has averaged $0/month, and operational expenses have averaged $400/month, for an average burn rate of $400 per month. Our intent is to be profitable in 36 months.
Since the date of our financials. nothing has changed. We provided our current assessment from our accredited CPA of our balance sheet, and the assessment of pre-revenue, supports this.
We will continue to be pre-revenue with no incoming accounts receivables from our application. Although we have pending Letters of Intent from key potential customers, that will be likely be our first customers upon completion of our beta and Pilot Program.
We need a total of $3M in working capital to reach a revenue-generating point. Our plan is to reach that point by Q3 2021. Six months later, we hope to be generating $416,000/month in revenues and $250,000/month in expenses.
We have boot strapped expenses and development costs since inception. We feel confident in successfully completing this initial round of crowdfunding to help with our upcoming expenses.
The largest risk which is also a direct effect for failure is the adoption into the medical first responders segment, and acceptance of use within the medical community. We have already taken a proactive approach to this, by adding key industry medical and first responder leaders into our Board of Directors/Advisors team. We have also implemented surveys and targeted surveys that support our development.
A successful role out throughout the cross segments, in unison, has to be paramount toward any successful scalability. Each of our customer segments are ecosystems that can feed each other for successful adoption and long term viability.
The biggest development hurdle at this point is gathering more artificial intelligence data, augmented analytics, and incorporating them onto the current state, proof of conception, and integration for beta product launch.
Rose Pizzo is a current co-founder but is part-time. Our initial crowdsourcing raise will dictate her coming in full time and executing her role. The principal co-founders, Jonathan and Michael are supporting many of her duties prior to initial crowdsource raise.
We currently have two provisional patents for software process design. The initial patent application is dated December 8, 2019, and has up to December 7th, 2020 to fully complete the patent cycle. The integration of key components of the design and algorithm is time sensitive toward this date. An extension is allowed but could further delay the beta/pilot program release for the signed letters of intent from customers.
The future success depends of a small co-founders management team. The loss of either one of the principal Co-Founders, may have an adverse effect on the company's progression. The only assurance for backup support would come from key Board of Directors.
Rose Pizzo is a part-time officer. As such, it is likely that the company will not make the same progress as it would if that were not the case.
Already have a Wefunder account? Login
Don't have a Wefunder account? Signup